Antibody-drug conjugates and anticancer agents

Abstract

The objective is to provide an iron chelating agent that can specifically reach cancer cells. [Means] An antibody-drug conjugate comprising an antibody having properties to bind to cancer cells, an iron chelating agent, and a crosslinking agent that connects them.

Claims

1. Antibodies having properties to bind to cancer cells, iron chelating agents, and crosslinking agents that connect these, An antibody-drug conjugate equipped with the following features.

2. The antibody-drug conjugate according to claim 1, wherein the iron chelating agent is a compound having the following structure.

3. The antibody-drug conjugate according to claim 1, wherein the antibody having the property of binding to the cancer cells is any of the following: anti-EGFR antibody, anti-VEGFR antibody, anti-HER2 antibody, anti-HER3 antibody, anti-FFFR antibody, anti-IGFR antibody, anti-HGFR antibody, anti-PDGFR antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD33 antibody, anti-CD52 antibody, anti-CEA antibody, anti-EpCAM antibody, anti-Nectin-4 antibody, anti-TROP-2 antibody, or anti-PD-L1 antibody.

4. The antibody-drug conjugate according to claim 1, wherein the crosslinking agent is any of Sulfo-GMBS, Sulfo-EMCS, Sulfo-HMCS, Sulfo-KMUS, Sulfo-SMCC, Sulfo-AC5-SPDP, or DTSSP.

5. An anticancer agent comprising an antibody-drug conjugate as described in any one of claims 1 to 4 as an active ingredient.

Images